Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642183 · ClinicalTrials.gov registry record
Single In-Clinic Encounter With the Notal Vision Home OCT
A clinical trial, sponsored by Notal Vision.
- Completed
- Registry status
- 70
- Enrollment target
NCT04642183: Completed study, sponsored by Notal Vision.
NCT04642183 is a clinical trial that has completed, run by Notal Vision. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04642183 has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
Study Summary
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment. All subjects will be enrolled at 1 site in the United States. in this study patients will be placed in a room with the Notal Vision Home OCT device and following a completion of a self tutorial will perform 3 unsupervised self-scans on each study eye (with a rest of \~5 minutes between self-scans). at the end of the testing sessions, the subject will be asked to complete subject user questionnaire.
Primary Outcome
Percentage of subjects who were able to perform a full self-scanning and generate a retinal volume scan.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2021-09-30 |
What the finished NCT04642183 record still lists
NCT04642183 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04642183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04642183 about?
NCT04642183 is a clinical study titled "Single In-Clinic Encounter With the Notal Vision Home OCT". this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet...
What is the current status of trial NCT04642183?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2020-11-16. Estimated completion is 2021-09-30.
Who is sponsoring clinical trial NCT04642183?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI